PDE7A and myeloid sarcoma: Our results lead us to propose these dual PDE7-GSK3 inhibitors, especially VP3.15 with its good oral bioavailability and CNS penetration, as potential combined anti-inflammatory and pro-remyelinating therapies for MS.